½ÃÀ庸°í¼­
»óǰÄÚµå
1600664

CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå : À¯Çüº°, ¿¬±¸ ´Ü°èº°, Ä¡·á ¿µ¿ªº°, ºÐÀÚ À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 196 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀåÀÇ 2023³â ±Ô¸ð´Â 870¾ï ´Þ·¯, 2024³â¿¡´Â 963¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 10.97%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 1,803¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Á¦¾à, »ý¸í°øÇÐ, ÀÇ·á±â±â »ê¾÷¿¡¼­ CRO(Contract Research Organization: ÀǾàǰ °³¹ß À§Å¹±â°ü) ¼­ºñ½º´Â ¿¬±¸ ¼­ºñ½º ¾Æ¿ô¼Ò½ÌÀ» ÅëÇØ Á¦Ç° °³¹ß °¡¼ÓÈ­, ºñ¿ë Àý°¨, ½ÅÁ¦Ç° Ãâ½ÃÀÇ È¿À²È­¸¦ ½ÇÇöÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù, Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. CRO ¼­ºñ½ºÀÇ Çʿ伺Àº Á¡Á¡ ´õ º¹ÀâÇØÁö´Â ±ÔÁ¦ ȯ°æ, ÀǾàǰ °³¹ß ºñ¿ëÀÇ »ó½Â, ¸ðµç ±â¾÷ÀÌ ÀÚüÀûÀ¸·Î º¸À¯ÇÏÁö ¸øÇÑ Àü¹® Áö½ÄÀÇ Çʿ伺À¸·Î ÀÎÇØ ¹ß»ýÇϸç, ÃÊ±â ´Ü°è °³¹ß, ÀÓ»ó½ÃÇè °ü¸®, ½ÇÇè½Ç ¼­ºñ½º, µ¥ÀÌÅÍ °ü¸®, Á¦¾à ÄÁ¼³ÆÃ µîÀÌ Æ÷ÇԵ˴ϴÙ. CRO ¼­ºñ½ºÀÇ ¿ëµµ´Â ¿¬±¸°³¹ßÀÇ ´Ù¾çÇÑ ´Ü°è¿¡ °ÉÃÄ ÀÖÀ¸¸ç, ÀÚ¿øÀ» ÃÖÀûÈ­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô À¯¿¬¼º°ú È®À强À» Á¦°øÇÕ´Ï´Ù. ÃÖÁ¾ »ç¿ë »ê¾÷¿¡´Â Á¦¾àȸ»ç, »ý¸í°øÇÐ ±â¾÷, ÀÇ·á±â±â Á¦Á¶¾÷ü, Çмú ¿¬±¸ ±â°ü, Á¤ºÎ ¿¬±¸ ±â°ü µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 870¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 963¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 1,803¾ï 6,000¸¸ ´Þ·¯
CAGR(%) 10.97%

¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ ±Þ¼ÓÇÑ ¹ßÀü, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É, Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ R&D ºñ¿ë Áõ°¡ µî ¿©·¯ °¡Áö ¼ºÀå ¿äÀο¡ ÀÇÇØ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·áÀÇ ºÎ»ó°ú ÇÔ²² À¯ÀüüÇÐ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º µî »õ·Î¿î ºÐ¾ß·ÎÀÇ ¼­ºñ½º Á¦°ø È®´ë´Â ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·«Àû Á¦ÈÞ¿Í Àμö´Â ¼­ºñ½º ¿ª·®°ú Áö¸®Àû ¹üÀ§¸¦ °­È­ÇÏ¿© Å« °æÀï ¿ìÀ§¸¦ °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ¸¹Àº ÅõÀÚ¿Í Àü¹®¼ºÀ» ÇÊ¿ä·Î ÇÏ´Â µ¥ÀÌÅÍ º¸¾È°ú ±ÔÁ¦ Áؼö, °¡°Ý Àü·«°ú ¼öÀÍ·üÀ» ¾Ð¹ÚÇÏ´Â ±âÁ¸ ¹× ½Å»ý ±â¾÷ °£ÀÇ Ä¡¿­ÇÑ °æÀïÀº °úÁ¦·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀáÀçÀûÀÎ ¾÷¹« È¿À²¼º ÀúÇÏ¿Í ¼­ºñ½º Á¦°ø »ê¾÷ÀÇ °æÁ¦ »óȲ¿¡ µû¶ó ´Þ¶óÁú ¼ö ÀÖ´Ù´Â ÇѰ赵 ÀÖ½À´Ï´Ù.

ÅõÀÚ ´ë»ó Çõ½Å ºÐ¾ß¿¡´Â °í±Þ µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç °³¹ß, AI ¹× ¸Ó½Å·¯´×À» ÅëÇÑ ÀÓ»ó½ÃÇè ±â¼ú °­È­, ÀÓ»ó½ÃÇè µî·Ï ¹× À¯ÁöÀ²À» °³¼±Çϱâ À§ÇÑ È¯ÀÚ Á᫐ Á¢±Ù ¹æ½Ä¿¡ ÁýÁßÇÏ´Â µî CRO ½ÃÀåÀÇ ¿ªµ¿ÀûÀÌ°í °æÀïÀûÀΠƯ¼ºÀ¸·Î ÀÎÇØ ±â¼ú ¹ßÀü°ú »ê¾÷ ¼ö¿äÀÇ º¯È­¿¡ Áö¼ÓÀûÀ¸·Î ÀûÀÀÇØ¾ß ÇÕ´Ï´Ù. ±â¼ú ¹ßÀü°ú »ê¾÷ ¼ö¿äÀÇ º¯È­¿¡ ²÷ÀÓ¾øÀÌ ÀûÀÀÇØ¾ß ÇÕ´Ï´Ù. ±â¼ú ÅëÇÕÀ» Ȱ¿ëÇÏ°í ¹ÎøÇÑ ¿î¿µ ¸ðµ¨À» À¯ÁöÇÒ ¼ö ÀÖ´Â ±â¾÷Àº °ü·Ã ½ÃÀå À§ÇèÀ» ÁÙÀ̸鼭 ¼ºÀå ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ´Â À¯¸®ÇÑ À§Ä¡¿¡ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀǾàǰ °³¹ß ´ëÇà ¼­ºñ½º ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¦¾à ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡
    • »ý¹°ÇÐÀû Á¦Á¦¿Í ÇÙÀǾàǰÀÇ º¸±Þ È®´ë
    • ¿¬±¸ Ȱµ¿ÀÇ ¾Æ¿ô¼Ò½Ì ¼­ºñ½º µµÀÔ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • µ¥ÀÌÅÍ °ü¸® ¹× ¹«°á¼º¿¡ ´ëÇÑ ¿ì·Á
  • ½ÃÀå ±âȸ
    • CRO¸¦ ÅëÇÑ µðÁöÅÐÈ­µÈ ¹ÎøÇÑ Á¦Á¶ ¹× R&D ±â¼ú µµÀÔ
    • º¸´Ù Áøº¸µÈ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á¸¦ À§ÇÑ »õ·Î¿î ÀÓ»ó½ÃÇè ¼³°è ¹× ÇÁ·ÎÅäÄÝ¿¡ ÁßÁ¡À» µÓ´Ï´Ù.
  • ½ÃÀå °úÁ¦
    • Àӻ󿬱¸ÀÇ È¯ÀÚ È®º¸ ¹× À¯Áö ¹®Á¦

Portre's Five Forces: ÀǾàǰ °³¹ß À§Å¹±â°ü ¼­ºñ½º ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀǾàǰ °³¹ß ¼öʱâ°ü ¼­ºñ½º ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼®

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Á¦¾à °³¹ß ¾Æ¿ô¼Ò½Ì ¼­ºñ½º ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀǾàǰ °³¹ß ¼öʱâ°ü ¼­ºñ½º ½ÃÀå¿¡¼­ÀÇ °æÀï»óȲ ÆÄ¾Ç

Á¦¾à °³¹ß ¾Æ¿ô¼Ò½Ì ¼­ºñ½º ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀǾàǰ °³¹ß À§Å¹±â°ü ¼­ºñ½º ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Á¦¾à °³¹ß À§Å¹±â°ü ¼­ºñ½º ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ÀǾàǰ °³¹ß À§Å¹±â°ü ¼­ºñ½º ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå : À¯Çüº°

  • ÀÓ»ó ¿¬±¸ ¼­ºñ½º
  • ÄÁ¼³ÆÃ ¼­ºñ½º
  • µ¥ÀÌÅÍ °ü¸® ¼­ºñ½º
  • ÃÊ±â ´Ü°è °³¹ß ¼­ºñ½º
    • È­ÇÐ/Á¦Á¶/°ü¸®
    • Discovery ¿¬±¸
    • ÀüÀÓ»ó ¼­ºñ½º
      • ¾à¹°µ¿ÅÂÇÐ/¾à·ÂÇÐ
      • µ¶¼º ½ÃÇè
  • ½ÇÇè½Ç ¼­ºñ½º
    • ºÐ¼® ½ÃÇè
      • È®½Ç ¸®½º Å×½ºÆ®
      • ¹°¸®Àû Ư¼º
      • ¿øÀç·á Å×½ºÆ®
      • ¾ÈÁ¤¼º Å×½ºÆ®
    • »ýü ºÐ¼® ½ÃÇè

Á¦7Àå CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå : Æ®¶óÀ̾ó ´Ü°èº°

  • ´Ü°è I
  • ´Ü°è II
  • ´Ü°è III
  • ´Ü°è IV

Á¦8Àå CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå : Ä¡·á ¿µ¿ªº°

  • ½ÉÇ÷°ü Áúȯ
  • ÇǺΰú
  • À§Àå
  • ºñ´¢±â ¹× ¿©¼º °Ç°­
  • Ç÷¾×ÇÐ
  • ¸é¿ª Áúȯ
  • °¨¿°Áõ
  • ´ë»çÁúȯ/³»ºÐºñÇÐ
  • ½Å°æÇÐ
  • Á¾¾çÇÐ
  • ¾È°ú
  • Á¤½ÅÀÇÇÐ
  • È£Èí±â Áúȯ

Á¦9Àå CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå : ºÐÀÚ À¯Çüº°

  • ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á Áúȯ
  • ¹é½Å

Á¦10Àå CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Çмú±â°ü
  • ÀÇ·á±â±â ±â¾÷
  • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü) ¼­ºñ½º ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • AccuLab Life Sciences
  • ACTIVA-CRO
  • Advanced Clinical Research Services, LLC
  • BioAgile Therapeutics Pvt. Ltd.
  • Caidya
  • Calian Group Ltd.
  • Celerion, Inc.
  • Charles River Laboratories International, Inc.
  • Clinical Trial Service B.V. by PCM Trials
  • Cromsource by ClinChoice
  • CTI Clinical Trial & Consulting
  • Distefar del Sur SL
  • Ergomed PLC
  • Firma Clinical Research, LLC
  • Frontage Holdings Corporation
  • Geistek Pharma S.L.
  • HCL Technologies Limited
  • Icon PLC
  • INQUIS
  • IQVIA Holdings Inc.
  • KCR S.A.
  • Laboratory Corporation of America Holdings
  • Leon Research, S.L.
  • Linical Co., Ltd.
  • Medpace Holdings, Inc.
  • Novotech Health Holdings
  • OPIS S.r.l.
  • Oxon Epidemiology, S.L.
  • Parexel International Corporation
  • Pepgra
  • Pharmaron Beijing Co., Ltd.
  • Pivotal, S.L.U.
  • PPD Inc. by Thermo Fisher Scientific Inc.
  • Prometrika, LLC
  • ProRelix Services LLP
  • PSI CRO AG
  • QualitecFarma S.L.
  • SGS S.A.
  • Syncro Clinical Research SRL
  • Syneos Health, Inc.
  • The Emmes Company, LLC
  • Veeda Clinical Research Limited
  • Vial Health Technology, Inc.
  • Worldwide Clinical Trials Holdings Inc.
  • WuXi AppTec Co., Ltd.
  • X7 Research
LSH

The Contract Research Organization Services Market was valued at USD 87.00 billion in 2023, expected to reach USD 96.31 billion in 2024, and is projected to grow at a CAGR of 10.97%, to USD 180.36 billion by 2030.

Contract Research Organization (CRO) services play a critical role in the pharmaceutical, biotechnology, and medical device industries by providing outsourced research services to accelerate product development, reduce costs, and improve the efficiency of getting new products to market. These services encompass early-phase development, clinical trial management, laboratory services, data management, and regulatory consulting, among others. The necessity for CRO services is driven by increasingly complex regulatory environments, the rising costs of drug development, and the need for specialized expertise that not all companies possess in-house. Their application spans various stages of research and development, offering flexibility and scalability to companies looking to optimize their resources. End-use industries include pharmaceuticals, biotechnology firms, and medical device manufacturers, along with academic and government research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 87.00 billion
Estimated Year [2024] USD 96.31 billion
Forecast Year [2030] USD 180.36 billion
CAGR (%) 10.97%

The market is influenced by several growth factors, such as rapid advancements in biotechnology, a greater emphasis on personalized medicine, and increased R&D expenditure by pharmaceutical and biotechnology companies. Potential opportunities lie in expanding service offerings to include emerging fields like genomics and bioinformatics, which are gaining traction due to the rise of precision medicine. Strategic partnerships and acquisitions can enhance service capabilities and geographical reach, providing significant competitive advantages. Challenges include maintaining data security and regulatory compliance, which require significant investment and expertise, and the intense competition among established and emerging players, which pressures pricing strategies and margins. Limitations also include potential operational inefficiencies and dependence on the economic health of the industries they serve.

Innovation areas ripe for investment include developing advanced data analytics solutions, enhancing clinical trial technologies through AI and machine learning, and focusing on patient-centric approaches that improve enrollment and retention in trials. The nature of the CRO market is dynamic and competitive, necessitating continual adaptation to technological advancements and shifting industry demands. Companies that can leverage technological integration and maintain agile operational models are well-positioned to capture growth opportunities while mitigating associated market risks.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Contract Research Organization Services Market

The Contract Research Organization Services Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing investments in pharmaceutical research and development
    • Growing penetration of biologics and nuclear medicines
    • Rise in adoption of outsourced services for research activities
  • Market Restraints
    • Concerns associated with data management and integrity
  • Market Opportunities
    • Adoption of digitized and agile manufacturing and research development techniques by CROs
    • Emphasis on novel clinical trial designs and protocols for more advanced cell and gene therapy
  • Market Challenges
    • Issues of patient recruitment and retention for clinical research

Porter's Five Forces: A Strategic Tool for Navigating the Contract Research Organization Services Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Contract Research Organization Services Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Contract Research Organization Services Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Contract Research Organization Services Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Contract Research Organization Services Market

A detailed market share analysis in the Contract Research Organization Services Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Contract Research Organization Services Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Contract Research Organization Services Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Contract Research Organization Services Market

A strategic analysis of the Contract Research Organization Services Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Contract Research Organization Services Market, highlighting leading vendors and their innovative profiles. These include AccuLab Life Sciences, ACTIVA-CRO, Advanced Clinical Research Services, LLC, BioAgile Therapeutics Pvt. Ltd., Caidya, Calian Group Ltd., Celerion, Inc., Charles River Laboratories International, Inc., Clinical Trial Service B.V. by PCM Trials, Cromsource by ClinChoice, CTI Clinical Trial & Consulting, Distefar del Sur SL, Ergomed PLC, Firma Clinical Research, LLC, Frontage Holdings Corporation, Geistek Pharma S.L., HCL Technologies Limited, Icon PLC, INQUIS, IQVIA Holdings Inc., KCR S.A., Laboratory Corporation of America Holdings, Leon Research, S.L., Linical Co., Ltd., Medpace Holdings, Inc., Novotech Health Holdings, OPIS S.r.l., Oxon Epidemiology, S.L., Parexel International Corporation, Pepgra, Pharmaron Beijing Co., Ltd., Pivotal, S.L.U., PPD Inc. by Thermo Fisher Scientific Inc., Prometrika, LLC, ProRelix Services LLP, PSI CRO AG, QualitecFarma S.L., SGS S.A., Syncro Clinical Research SRL, Syneos Health, Inc., The Emmes Company, LLC, Veeda Clinical Research Limited, Vial Health Technology, Inc., Worldwide Clinical Trials Holdings Inc., WuXi AppTec Co., Ltd., and X7 Research.

Market Segmentation & Coverage

This research report categorizes the Contract Research Organization Services Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Clinical Research Services, Consulting Services, Data Management Services, Early Phase Development Services, and Laboratory Services. The Early Phase Development Services is further studied across Chemistry, Manufacturing & Control, Discovery Studies, and Preclinical Services. The Preclinical Services is further studied across Pharmacokinetics/Pharmacodynamics and Toxicology Testing. The Laboratory Services is further studied across Analytical Testing and Bioanalytical Testing. The Analytical Testing is further studied across Batch Release Testing, Physical Characterization, Raw Material Testing, and Stability Testing.
  • Based on Trial Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Therapeutic Area, market is studied across Cardiovascular Disease, Dermatology, Gastrointestinal, Genitourinary & Women's Health, Hematology, Immunological Disorders, Infectious Diseases, Metabolic Disorders/Endocrinology, Neurology, Oncology, Ophthalmology, Psychiatry, and Respiratory Disorders.
  • Based on Molecule Type, market is studied across Cell & Gene Therapy Diseases and Vaccines.
  • Based on End-User, market is studied across Academic Institutes, Medical Device Companies, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing investments in pharmaceutical research and development
      • 5.1.1.2. Growing penetration of biologics and nuclear medicines
      • 5.1.1.3. Rise in adoption of outsourced services for research activities
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with data management and integrity
    • 5.1.3. Opportunities
      • 5.1.3.1. Adoption of digitized and agile manufacturing and research development techniques by CROs
      • 5.1.3.2. Emphasis on novel clinical trial designs and protocols for more advanced cell and gene therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Issues of patient recruitment and retention for clinical research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Adoption of clinical research services to manage the complexity and duration of clinical trials
    • 5.2.2. Trial Phase: Need for CROs with strong capabilities in real-world data and post-market support
    • 5.2.3. Therapeutic Area: Consistent preference for CRO services in oncology drug development activities
    • 5.2.4. End-User: Need for strong foundational research capabilities by academic and research institutions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Contract Research Organization Services Market, by Type

  • 6.1. Introduction
  • 6.2. Clinical Research Services
  • 6.3. Consulting Services
  • 6.4. Data Management Services
  • 6.5. Early Phase Development Services
    • 6.5.1. Chemistry, Manufacturing & Control
    • 6.5.2. Discovery Studies
    • 6.5.3. Preclinical Services
      • 6.5.3.1. Pharmacokinetics/Pharmacodynamics
      • 6.5.3.2. Toxicology Testing
  • 6.6. Laboratory Services
    • 6.6.1. Analytical Testing
      • 6.6.1.1. Batch Release Testing
      • 6.6.1.2. Physical Characterization
      • 6.6.1.3. Raw Material Testing
      • 6.6.1.4. Stability Testing
    • 6.6.2. Bioanalytical Testing

7. Contract Research Organization Services Market, by Trial Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Contract Research Organization Services Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular Disease
  • 8.3. Dermatology
  • 8.4. Gastrointestinal
  • 8.5. Genitourinary & Women's Health
  • 8.6. Hematology
  • 8.7. Immunological Disorders
  • 8.8. Infectious Diseases
  • 8.9. Metabolic Disorders/Endocrinology
  • 8.10. Neurology
  • 8.11. Oncology
  • 8.12. Ophthalmology
  • 8.13. Psychiatry
  • 8.14. Respiratory Disorders

9. Contract Research Organization Services Market, by Molecule Type

  • 9.1. Introduction
  • 9.2. Cell & Gene Therapy Diseases
  • 9.3. Vaccines

10. Contract Research Organization Services Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic Institutes
  • 10.3. Medical Device Companies
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Contract Research Organization Services Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Contract Research Organization Services Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Contract Research Organization Services Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Lindus Health revolutionizes dermatology trials with 'all-in-one dermatology CRO' launch
    • 14.3.2. Allucent secures 5-Year BARDA partnership to advance decentralized clinical trials for medical countermeasures
    • 14.3.3. Strategic merger between palleos healthcare GmbH and OCT Clinical GmbH expands clinical research in Europe
    • 14.3.4. Veeda Clinical Research Bolsters Global Presence with Strategic Acquisition of European CRO, Heads
    • 14.3.5. Innovative Partnership between EUROAPI and SpiroChem Revolutionizes CRO-CDMO Integration for Drug Development
    • 14.3.6. Maridose Launches Innovative CRO Group for Cannabis-Based Drug Development
    • 14.3.7. Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners
    • 14.3.8. Everest Clinical Research Announces the Acquisition of August Research
    • 14.3.9. PRC Clinical and TrialHub Unite to Elevate Clinical Trial Efficiency and Patient Recruitment
    • 14.3.10. OrganaBio Launches Innovative Cell Processing and Cryopreservation Services to Support Decentralized Clinical Trials
    • 14.3.11. MedRhythms Choses Curavit as its Contract Research Organization (CRO) for a Chronic Stroke Decentralized Clinical Trial
    • 14.3.12. Innovating Healthcare through a Strategic Partnership between Worldwide Clinical Trials and Every Cure
    • 14.3.13. ClinChoice Expands Global Reach with Strategic Acquisition of CROMSOURCE
    • 14.3.14. Avania Acquires MAXIS: Enhancing Medtech Development and Commercialization
    • 14.3.15. TFS HealthScience Broadens Its Horizons with Appletree CI Group Acquisition
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Veeda Clinical Research Limited

Companies Mentioned

  • 1. AccuLab Life Sciences
  • 2. ACTIVA-CRO
  • 3. Advanced Clinical Research Services, LLC
  • 4. BioAgile Therapeutics Pvt. Ltd.
  • 5. Caidya
  • 6. Calian Group Ltd.
  • 7. Celerion, Inc.
  • 8. Charles River Laboratories International, Inc.
  • 9. Clinical Trial Service B.V. by PCM Trials
  • 10. Cromsource by ClinChoice
  • 11. CTI Clinical Trial & Consulting
  • 12. Distefar del Sur SL
  • 13. Ergomed PLC
  • 14. Firma Clinical Research, LLC
  • 15. Frontage Holdings Corporation
  • 16. Geistek Pharma S.L.
  • 17. HCL Technologies Limited
  • 18. Icon PLC
  • 19. INQUIS
  • 20. IQVIA Holdings Inc.
  • 21. KCR S.A.
  • 22. Laboratory Corporation of America Holdings
  • 23. Leon Research, S.L.
  • 24. Linical Co., Ltd.
  • 25. Medpace Holdings, Inc.
  • 26. Novotech Health Holdings
  • 27. OPIS S.r.l.
  • 28. Oxon Epidemiology, S.L.
  • 29. Parexel International Corporation
  • 30. Pepgra
  • 31. Pharmaron Beijing Co., Ltd.
  • 32. Pivotal, S.L.U.
  • 33. PPD Inc. by Thermo Fisher Scientific Inc.
  • 34. Prometrika, LLC
  • 35. ProRelix Services LLP
  • 36. PSI CRO AG
  • 37. QualitecFarma S.L.
  • 38. SGS S.A.
  • 39. Syncro Clinical Research SRL
  • 40. Syneos Health, Inc.
  • 41. The Emmes Company, LLC
  • 42. Veeda Clinical Research Limited
  • 43. Vial Health Technology, Inc.
  • 44. Worldwide Clinical Trials Holdings Inc.
  • 45. WuXi AppTec Co., Ltd.
  • 46. X7 Research
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦